Security Snapshot

Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) Institutional Ownership

CUSIP: 78667J108

13F Institutional Holders and Ownership History from Q3 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

2

Shares (Excl. Options)

22,221

Price

$14.85

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Type / Class
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
Symbol
SAGE
Shares outstanding
62,650,155
Price per share
$8.68
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
22,221
Total reported value
$460,009
Share change
-4,490
Value change
-$38,973
Number of holders
2
Price from insider filings
$8.68
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") is tracked under CUSIP 78667J108.
  • 2 institutions reported positions in Q4 2025.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 2 to 0 between Q4 2025 and Q1 2026.
  • Reported value moved from $460,009 to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 2 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 78667J108?
CUSIP 78667J108 identifies SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.2% $34,471,350 4,425,077 BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 5.2% -34% $29,784,114 -$14,339,987 3,265,802 -32% The Vanguard Group 30 Jun 2025
RTW INVESTMENTS, LP 4.9% $23,388,462 3,002,370 RTW Investments, LP 31 Dec 2024
BB BIOTECH AG 1.9% $9,180,538 1,178,503 BB Biotech AG 13 Jan 2025
MORGAN STANLEY 1.6% -83% $7,886,105 -$27,503,802 1,012,337 -78% Morgan Stanley 28 Feb 2025
FMR LLC 0.8% -84% $3,902,130 -$28,169,341 500,915 -88% FMR LLC 28 Feb 2025

As of 31 Dec 2025, 2 institutional investors reported holding 22,221 shares of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE). This represents 0.04% of the company’s total 62,650,155 outstanding shares.

Institutional Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 0 $0 -$460,000 $8.68 0
2025 Q4 22,221 $460,009 -$38,973 $14.85 2
2025 Q3 26,711 $493,982 -$445,228,929 $8.84 4
2025 Q2 48,874,647 $445,736,286 -$15,762,130 $9.12 190
2025 Q1 51,753,624 $411,497,036 +$29,109,546 $7.95 196
2024 Q4 51,167,791 $277,852,513 -$6,197,488 $5.43 173
2024 Q3 51,256,195 $370,077,943 -$24,510,910 $7.22 171
2024 Q2 53,511,146 $581,112,272 -$70,089,721 $10.86 190
2024 Q1 58,440,998 $1,095,196,207 +$43,391,410 $18.74 199
2023 Q4 56,110,184 $1,215,929,511 -$60,792,173 $21.67 196
2023 Q3 58,785,676 $1,209,823,569 -$2,528,143 $20.58 192
2023 Q2 54,096,461 $2,543,396,226 +$53,758,888 $47.02 222
2023 Q1 52,951,870 $2,221,541,781 +$61,109,823 $41.96 210
2022 Q4 51,655,406 $1,969,597,318 +$218,675 $38.14 200
2022 Q3 51,490,290 $2,016,420,954 +$13,625,356 $39.16 182
2022 Q2 51,071,239 $1,649,759,751 +$39,700,428 $32.30 188
2022 Q1 49,945,298 $1,653,434,346 -$25,580,877 $33.10 190
2021 Q4 50,185,286 $2,135,089,557 +$29,204,332 $42.54 201
2021 Q3 49,060,569 $2,173,846,483 -$115,480,957 $44.31 215
2021 Q2 50,613,429 $2,875,212,413 -$158,839,086 $56.81 246
2021 Q1 53,088,674 $3,974,807,423 -$71,753,377 $74.85 254
2020 Q4 53,803,776 $4,654,671,800 +$61,838,572 $86.51 244
2020 Q3 53,660,582 $3,277,403,116 -$18,817,366 $61.12 224
2020 Q2 54,023,562 $2,247,849,991 +$2,123,337 $41.58 207
2020 Q1 55,020,519 $1,580,165,244 -$222,075,767 $28.72 213
2019 Q4 55,964,444 $4,040,118,901 -$417,728,404 $72.19 256
2019 Q3 58,267,547 $8,175,198,734 +$23,489,599 $140.29 273
2019 Q2 58,089,604 $10,632,783,890 +$989,879,978 $183.09 265
2019 Q1 56,290,569 $8,953,438,249 +$1,124,287,863 $159.05 258
2018 Q4 49,737,058 $4,761,682,266 +$3,495,565 $95.79 241
2018 Q3 49,008,712 $6,924,204,711 +$56,782,421 $141.25 272
2018 Q2 48,621,395 $7,610,500,125 +$162,362,469 $156.53 265
2018 Q1 47,521,631 $7,647,354,047 +$644,797,785 $161.07 243
2017 Q4 44,056,451 $7,257,119,465 +$681,492,435 $164.71 220
2017 Q3 39,314,584 $2,450,400,062 +$48,577,382 $62.30 168
2017 Q2 38,446,334 $3,055,447,026 +$50,629,626 $79.64 187
2017 Q1 37,871,607 $2,691,023,691 +$271,054,103 $71.07 185
2016 Q4 36,733,208 $1,875,786,404 -$50,072,012 $51.06 161
2016 Q3 37,761,752 $1,738,397,667 +$400,822,533 $46.05 150
2016 Q2 30,208,087 $911,383,018 +$28,986,285 $30.13 137
2016 Q1 29,073,553 $931,907,546 +$174,147,459 $32.06 138
2015 Q4 23,473,499 $1,368,495,352 +$157,290,312 $58.30 135
2015 Q3 27,212,732 $1,151,636,509 +$26,731,112 $42.32 126
2015 Q2 26,411,389 $1,927,998,498 +$372,239,794 $73.00 120
2015 Q1 21,505,189 $1,080,202,161 +$87,874,721 $50.23 90
2014 Q4 19,746,808 $722,803,309 +$22,868,587 $36.60 71
2014 Q3 18,894,149 $595,167,000 +$595,167,000 $31.50 50
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .